Replies: 1 comment
|
Thanks for framing this so carefully — especially the "not a replacement for My honest answer to Q1 is: the goal is real, but I don't think the mechanism clears its own bar yet. A Labs system is itself permanent machinery — a registry, a settings surface, diagnostic identity, exit tracking. The manager has to be cheaper than what it manages, and right now Maka has two facts that shrink what would be left for it:
On Q5, if Maka ever does adopt in-product trials, the one constraint I'd consider non-negotiable: expiration must be mechanical, not procedural. An experiment carries an expiry date in code and simply stops activating after it; "remember to remove the flag" as a process rule is how temporary branches become permanent compatibility paths. Per-session activation scope (Q3) would be the natural fit with that. So: worth revisiting once nightly feedback shows a recurring class of changes that genuinely can't be evaluated there — at that point the evidence for the mechanism's own maintenance cost would exist too. (Drafted with AI assistance; release cadence and nightly-channel claims verified against the repository.) 中文版本感谢把这个想法整理得这么周全——尤其是"不替代 我对 Q1 的诚实回答是:需求是真的,但这个机制目前还过不了它自己那关。 Labs 系统本身就是一套永久设施——注册表、设置界面、诊断标识、退出跟踪。管理者必须比被管理的东西便宜,而 Maka 当前有两个事实会压缩它能发挥的空间:
关于 Q5,如果未来真的引入产品内试用,我认为有一条约束不可协商:过期必须靠机制,不能靠流程。 实验在代码里携带到期日,到期后自动停止激活;"记得删 flag"这种流程性约定,正是临时分支变成永久兼容路径的原因。按 Session 粒度激活(Q3)会是比较自然的搭配。 所以建议是:等 nightly 的反馈真的暴露出一类"在 nightly 里无法评估"的改动时再重启这个话题——到那时,这套机制自身维护成本的证据也就有了。 (本评论由 AI 辅助起草;发布节奏与 nightly 通道的论断均已对照仓库核实。) |
Uh oh!
There was an error while loading. Please reload this page.
Maka is evolving quickly, and some changes are difficult to judge from implementation review or benchmarks alone. Users may need to try a behavior in real work, compare it with the stable behavior, and switch back before the project decides whether to keep it.
Today we do not have one user-facing way to offer that kind of trial. A change is usually either shipped as the product behavior, kept behind an ad hoc flag, or left for contributors to build locally.
Some examples of changes that could benefit from an opt-in trial are:
These are examples only. This discussion is not intended to decide the design or adoption of any of them.
Question
Should Maka introduce an Experiments / Labs mechanism for users to enable selected experimental capabilities, try them in real workflows, provide feedback, and return to the stable behavior?
If we want this, a useful mechanism might provide:
This would be a product trial mechanism, not a replacement for
@maka/eval. Eval answers reproducible benchmark questions; Labs would help collect real-world usability and compatibility feedback that benchmarks may not expose.Questions to settle
The immediate decision here is only whether Maka needs this mechanism and what constraints it should have. Individual experimental features can continue to be discussed in their own threads.
AI assistance disclosure: Drafted and published with Codex at the author's direction.
All reactions